Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
German finance minister sees advantages of smartphones in schools - 2Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- 3Israel approves 19 new West Bank settlements in major annexation push
- 4New images reveal interstellar comet 3I/ATLAS approaching Earth
- 5Passenger Missing After Going Overboard Disney Cruise Ship
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- European Travel Objections for 2024
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- Eurovision Song Contest changes voting rules after controversial allegations against Israel
- Oldest evidence of human fire-making discovered at site in England
